A new angle in retinal diseases

Explore the role of the Ang–Tie pathway in retinal and choroidal vascular diseases.

What’s new on 
Eye On Angiopoietins?

Our September 2022 update brings new content and features including:

Discovering the role of Ang–Tie signalling in retinal vein occlusion

Learning about the role of pericytes in retinal vascular stability

Additional preclinical evidence on inflammation

watermark-hero@2x.png

Welcome to Eye On Angiopoietins

Discover how angiopoietins regulate vascular stability under normal conditions and drive vascular instability in retinal and choroidal vascular diseases.

Watch: Ang–Tie signalling: An animated journey

Looking beyond VEGF

Discover how signalling pathways beyond VEGF contribute to the pathogenesis of DME, nAMD, and RVO.

illustration-looking-beyond-vegf.svg

What are angiopoietins?

Explore the key players in the Ang–Tie pathway and journey through the milestone events in their discovery.

illustration-what-are-angiopoietins.svg

Angiopoietins in vascular instability

Discover how elevated Ang-2 and VEGF drive vascular instability, characterised by vascular leakage, inflammation, and neovascularisation.

illustration-angiopoietins-in-vascular-instability.svg

Test your knowledge

Take this short quiz to put your knowledge of angiopoietins to the test!

icon-test-your-knowledge.png

Explore the evidence

Review the data indicating the role of Ang-2 in driving vascular instability.

illustration-explore-the-evidence.svg

Eye Travel Systems

Experience an interactive journey through retinal vessels to explore the roles of Ang-2 and VEGF in DME and nAMD.

illustration-eye-travel-systems.svg

Useful resources

Access additional resources of interest to continue your understanding of the Ang–Tie pathway.

illustration-useful-resources.svg

Register your interest

Register to receive notifications from Roche Ophthalmology, including website updates and news about angiopoietins

icon-register-your-interest-desktop.png

Ang, angiopoietin; DME, diabetic macular edema; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion; Tie, tyrosine kinase with immunoglobulin-like domains; VEGF, vascular endothelial growth factor.

  1. Saharinen P, et al. Nat Rev Drug Discov. 2017;16:635–61
  2. Chakravarthy U, et al. Retina. 2018;38:343–51
  3. Swaroop A, et al. Annu Rev Genomics Hum Genet. 2009
  4. Ciulla TA, et al. Ophthalmol Retina. 2020;4:19–308
  5. Felcht M, et al. J Clin Invest. 2012;122:1991–2005
  6. Hakanpaa L, et al. Nat Commun. 2015;30;6:5962
  7. Regula JT, et al. EMBO Molecular Med. 2016;8(11):1265–88
  8. Huang H, et al. Nat Rev Cancer. 2010;10:575–85
  9. Klaassen I, et al. Prog Retin Eye Res. 2013;34:19–48
  10. Bolinger MT, et al. Int J Mol Sci. 2016;17:1498
  11. Fiedler U, Augustin HG. Trends Immunol. 2006;27:552–8
  12. Regula JT, et al. EMBO Mol Med. 2019;11:e10666
  13. Benest AV, et al. PLoS One. 2013;8:e70459
  14. Chakravarthy U, et al. Presented at ARVO May 2020, Virtual Meeting
  15. Fiedler U, et al. Nat Med. 2006;12:235–9

Explore how factors other than VEGF are involved in the pathogenesis of DME, nAMD, and RVO…

Continue to